Board approves unaudited results for quarter and half year ended September 30, 2026; limited review done
Board meeting outcome: the Board met on Wednesday, October 14, 2026 from 03:00 P.M. to 04:00 P.M. and approved the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2026.
By ScoutQuest · · 3 min read
- Standalone Total Revenue
- 9.18 for the quarter ended 30-09-2026 and 18.09 for the half year (₹ in Lakhs)
- Standalone Profit for the Period
- 15.29 for the quarter and 45.42 for the half year (₹ in Lakhs)
- Consolidated Profit/(Loss) from ordinary activities before tax
- (2.99) for the quarter and 3.65 for the half year (₹ in Lakhs)
Bacil Pharma Limited's Board of Directors met on Wednesday, October 14, 2026 at the Registered Office of the Company. The meeting commenced at 03:00 P.M. and concluded at 04:00 P.M.
Decisions taken
- The Board approved the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company.
- The results were reviewed and recommended by the Audit Committee and approved by the Board at its meeting held on 14-10-2026.
- The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format.
- The Company has only one reportable primary pharmaceutical business segment as per IND AS 108.
Review conclusion from the auditors
The Statutory Auditors carried out a "Limited Review" of the results. A limited review gives moderate assurance and is substantially less in scope than an audit. The report states that it is based solely on documents, explanations and representations provided by the management of the entity, and it concludes: "There is no other qualification in these regards on these financial results."
Standalone results, ₹ in Lakhs, as printed
- 'Total revenue': 9.18 for the quarter ended 30-09-2026, 8.91 for the quarter ended 30-06-2026, and 18.09 for the half year ended 30-09-2026.
- 'Total expenses': 5.93, 2.27 and 8.20 for the same periods.
- 'Profit / (Loss) from ordinary activities before tax': 3.25, 6.64 and 9.89.
- 'Profit/(Loss) for the Period': 15.29, 30.12 and 45.42.
- 'Earning Per Share (EPS) (Not annualised)': Basic 0.11, 0.22 and 0.33; Diluted 0.11, 0.22 and 0.33.
- Paid up Equity Share Capital (Face Value of Rs. 10 each): 1,397.03.
Consolidated results, ₹ in Lakhs, as printed
- 'Total revenue': 9.18, 8.91 and 18.09 for the same periods.
- 'Total expenses': 12.17, 2.27 and 14.44.
- 'Profit / (Loss) from ordinary activities before tax': (2.99), 6.64 and 3.65.
- 'Profit/(Loss) from ordinary activities after tax': (7.22), (1.61) and (8.83).
- 'Profit/(Loss) for the Period': 9.06, 30.12 and 39.18.
- 'Earning Per Share (EPS) (Not annualised)': Basic 0.06, 0.22 and 0.28; Diluted 0.06, 0.22 and 0.28.
Balance sheet, Rupees in Lacs, as printed
Standalone, as at 30th September, 2026 against as at 31st March, 2026
- 'Total' assets: 2534.21 against 2739.26.
- Equity Share capital 1397.02 against 1397.02; Other Equity 1130.19 against 1084.24.
- Borrowings 0.00 against 0.00; Provisions 0.00 against 238.06.
- Cash and cash equivalents 30.31 against 56.85.
Consolidated, as at 30th September, 2026 against as at 31st March, 2026
- 'Total' assets: 3081.30 against 2739.26.
- Equity Share capital 1398.12 against 1397.02; Other Equity 1123.95 against 1084.24.
- Borrowings 552.24 against 0.00.
- Cash and cash equivalents 97.41 against 56.85.
Cash flow statement, standalone, Amount in LAKH, as printed
- 'Net cash (used in)/ from generated from operating activities': (224.89) for the year ended 30.09.2026 against 171.46 for the year ended 31.03.2026.
- 'Net cash (used in)/ from generated from investing activities': 162.28 against (338.47).
- 'Net cash (used in)/ from generated from financing activities': 36.08 against (61.88).
- 'Cash and Cash equivalents at the end of the year': 30.31 against 56.85.
How to read these numbers
- Figures shown in brackets are negative, exactly as printed in the statements.
- The standalone statement presents the Company on its own; the consolidated statement presents the group as a whole.
- These results are unaudited and have been subjected to a limited review, which is not an audit.
- The standalone and consolidated numbers are stated in Lakhs/Lacs, so 9.18 means Rs. 9.18 lakh and 2534.21 means Rs. 2534.21 lakh.
Also from Bacil Pharma
Board meeting on 14 October 2026 to consider and approve unaudited results for the quarter and half year ended 30 September 2026
5 Oct 2026
More numbers
- Standalone 'Total revenue', quarter ended 30-09-2026 (₹ in Lakhs)9.18
- Standalone 'Profit/(Loss) for the Period', half year ended 30-09-2026 (₹ in Lakhs)45.42
- Standalone Basic EPS (Not annualised), quarter ended 30-09-20260.11
- Standalone 'Total' assets as at 30th September, 2026 (₹ in Lacs)2534.21
- Consolidated 'Profit/(Loss) before tax', quarter ended 30-09-2026 (₹ in Lakhs)(2.99)
- Consolidated 'Total' assets as at 30th September, 2026 (Rupees in Lacs)3081.30
- Consolidated Borrowings as at 30th September, 2026 (Rupees in Lacs)552.24
- Standalone Cash and cash equivalents at the end of the year (Amount in LAKH)30.31
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.